KRAS mutations influence the cellular behavior and response of CRC cells to a 5-Fluorouracil (FU) based radiochemotherapy combined with receptor tyrosine kinase inhibitors

Aims: Mutations of the proto-oncogene KRAS are supposed to lead to an increased activity of KRAS inducing a constitutive activation of the downstream MAPK signaling pathway. The aim of the work was to investigate the behavior of colorectal cancer cell line SW 480 with different mutations in KRAS and their response to a combined radiochemotherapy (RCT) in the absence or presence of different receptor tyrosine kinase inhibitors (RTKI). Methods: The colorectal cancer cell line SW 480 carrying either KRAS wild-type or the KRAS mutations p.G12V, p.G12D and p.G13D were used. Cell proliferation, migration and invasion…